On October 27, 2025, Heron Therapeutics, Inc. appointed Thomas Cusack to its Board of Directors for a term until the 2026 Annual Meeting, as per a Cooperation Agreement with Rubric Capital Management. This is a significant event, reflecting a strategic move in corporate governance.